

CLAIMS

1. A method for treating a cancer, which comprises administering a therapeutically effective amount of
5 trastuzumab to a patient in need thereof, in combination with an amount of dexrazoxane effective to ameliorate cardiotoxicity.

2. A method for treating a cancer, which comprises
10 administering a therapeutically effective amount of trastuzumab in association with an anthracycline to a patient in need thereof, in combination with an amount of dexrazoxane effective to ameliorate cardiotoxicity.

15 3. A method for treating a cancer, which comprises administering a therapeutically effective amount of trastuzumab in association with epirubicin to a patient in need thereof, in combination with an amount of dexrazoxane effective to ameliorate cardiotoxicity.

20 4. A method according to claim 1, wherein the cancer is a cancer overexpressing the human epidermal growth factor receptor 2 (HER2).

25 5. A method according to claim 4, wherein the cancer overexpressing the human epidermal growth factor receptor 2 (HER2) is selected from the group consisting of breast, uterine endometrium, pancreas, colon, ovaries, lung, stomach, salivary glands, head, and neck cancer.

6. A method according to claim 5, wherein the cancer is breast cancer.

5 7. A method according to claim 2, wherein the cancer is a cancer overexpressing the human epidermal growth factor receptor 2 (HER2).

8. A method according to claim 7, wherein the cancer
10 overexpressing the human epidermal growth factor receptor 2 (HER2) is selected from the group consisting of breast, uterine endometrium, pancreas, colon, ovaries, lung, stomach, salivary glands, head, and neck cancer.

15 9. A method according to claim 8, wherein the cancer is breast cancer.

10. A method according to claim 3, wherein the cancer is a
20 cancer overexpressing the human epidermal growth factor receptor 2 (HER2).

11. A method according to claim 10, wherein the cancer
overexpressing the human epidermal growth factor receptor 2 (HER2) is breast, uterine endometrium, pancreas, colon,
25 ovaries, lung, stomach, salivary glands, head, and neck cancer.

12. A method according to claim 11, wherein the cancer is breast cancer.

13. A method for ameliorating cardiotoxic effects caused by
5 trastuzumab when administered alone, which comprises administering an effective amount of dexrazoxane.

14. A method for ameliorating cardiotoxic effects caused by
trastuzumab when administered in combination with an
10 anthracycline, which comprises administering an effective amount of dexrazoxane.

15. A method for ameliorating cardiotoxic effects caused by
trastuzumab when administered in combination with epirubicin,
15 which comprises administering an effective amount of dexrazoxane.

16. A kit comprising:

- a. trastuzumab and a pharmaceutically acceptable carrier or
20 diluent in a first unit dosage form;
- b. dexrazoxane and a pharmaceutically acceptable carrier or
diluent in a second unit dosage form; and
- c. a container.

25 17. A kit comprising:

- a. trastuzumab and a pharmaceutically acceptable carrier or
diluent in a first unit dosage form;
- b. an anthacycline and a pharmaceutically acceptable
carrier or diluent in a second unit dosage form;
- 30 c. dexrazoxane and a pharmaceutically acceptable carrier or
diluent in a third unit dosage form; and
- d. a container.

18. A kit comprising:

- a. trastuzumab and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- 5 b. epirubicin and a pharmaceutically acceptable carrier or diluent in a second unit dosage form;
- c. dexrazoxane and a pharmaceutically acceptable carrier or diluent in a third unit dosage form; and
- d. a container.

10

19. A combined preparation for ameliorating cardiotoxicity selected from the group consisting of:

(a) trastuzumab and dexrazoxane; and

(b) trastuzumab, anthracycline, and dexrazoxane,

15

wherein each component of the combined preparation is administered simultaneously, separately, or sequentially.

20. Dexrazoxane for use in the manufacture of a medicament for ameliorating cardiotoxicity induced by trastuzumab.

20

21. Dexrazoxane for use in the manufacture of a medicament for ameliorating cardiotoxicity induced by trastuzumab in conjunction with an anthracycline.

25

22. Dexrazoxane for use in the manufacture of a medicament for ameliorating cardiotoxicity induced by trastuzumab in conjunction with epirubicin.